Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.
Status:
Unknown status
Trial end date:
2020-10-31
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy and safety of ethosuximide in the treatment of refractory
depressive disorder in adults. Half of participants will receive ethosuximide and
escitalopram in combination, while the other half will receive a placebo and escitalopram.